JY
SYRS

Jeff Yass’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Jeff Yass’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30,005
Closed -$108K – 13274
2024
Q2 		$155K Buy
+30,005
New +$158K ﹤0.01% 10660
2023
Q2 		– Sell
-19,633
Closed -$63.1K – 13363
2023
Q1 		$52.4K Sell
19,633
-23,614
-55% -$91.5K ﹤0.01% 11684
2022
Q4 		$155K Buy
43,247
+33,042
+324% +$143K ﹤0.01% 10458
2022
Q3 		$66K Sell
10,205
-12,666
-55% -$103K ﹤0.01% 12027
2022
Q2 		$220K Buy
22,871
+20,238
+769% +$189K ﹤0.01% 10406
2022
Q1 		$31K Sell
2,633
-13,969
-84% -$250K ﹤0.01% 12493
2021
Q4 		$541K Sell
16,602
-4,723
-22% -$191K ﹤0.01% 8980
2021
Q3 		$953K Buy
21,325
+6,674
+46% +$326K ﹤0.01% 7684
2021
Q2 		$798K Buy
14,651
+5,607
+62% +$332K ﹤0.01% 8385
2021
Q1 		$676K Sell
9,044
-764
-8% -$79.4K ﹤0.01% 8760
2020
Q4 		$1.06M Buy
9,808
+2,684
+38% +$245K ﹤0.01% 6583
2020
Q3 		$629K Buy
7,124
+4,850
+213% +$551K ﹤0.01% 7192
2020
Q2 		$242K Sell
2,274
-1,099
-33% -$98.6K ﹤0.01% 8712
2020
Q1 		$200K Buy
3,373
+1,560
+86% +$106K ﹤0.01% 8697
2019
Q4 		$125K Buy
1,813
+235
+15% +$14.3K ﹤0.01% 9039
2019
Q3 		$164K Buy
1,578
+140
+10% +$13.2K ﹤0.01% 9262
2019
Q2 		$133K Buy
+1,438
New +$100K ﹤0.01% 9462
2019
Q1 		– Sell
-2,643
Closed -$147K – 10023
2018
Q4 		$147K Buy
+2,643
New +$201K ﹤0.01% 8000

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Jeff Yass's SYRS Position: Q3 2024 in Review

Jeff Yass sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 30,005 shares — an estimated $108K sold.

Jeff Yass first reported a position in SYRS in Q4 2018 and held it in 18 quarters. The position peaked at $1.06M in Q4 2020. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • Jeff Yass reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Jeff Yass sold 30,005 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $108K.
  • Jeff Yass first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 18 quarters.
  • Jeff Yass's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.06M in Q4 2020.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.